Dilaudid patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9731082 FRESENIUS KABI USA Drug container
Apr, 2032

(8 years from now)

US9248229 FRESENIUS KABI USA Packaging system for oxygen-sensitive drugs
Mar, 2034

(10 years from now)

Dilaudid is owned by Fresenius Kabi Usa.

Dilaudid contains Hydromorphone Hydrochloride.

Dilaudid has a total of 2 drug patents out of which 0 drug patents have expired.

Dilaudid was authorised for market use on 11 January, 1984.

Dilaudid is available in injectable;injection dosage forms.

The generics of Dilaudid are possible to be released after 12 March, 2034.

Drugs and Companies using HYDROMORPHONE HYDROCHLORIDE ingredient

Market Authorisation Date: 11 January, 1984

Treatment: NA


How can I launch a generic of DILAUDID before it's drug patent expiration?
More Information on Dosage

DILAUDID family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic